Drug Trial Radar · NCT06393712
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
210
Actual
Start
May 17, 2024
Primary completion
Aug 9, 2027
Study completion Dec 14, 2029
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- May 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Conditions
- Cerebral Amyloid Angiopathy
Interventions
PlaceboDrug
Placebo will be administered intrathecally
ALN-APPDrug
ALN-APP will be administered intrathecally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-blind Treatment Period: Annualized Rate of New Lobar Cerebral Microbleeds (CMBs) Assessed on Magnetic Resonance Imaging (MRI) of Brain in Patients with Sporadic Cerebral Amyloid Angiopathy (sCAA)Time frame: Up to 24 months
Locations
57 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Orange, California
Clinical Trial Site
Palo Alto, California
Clinical Trial Site
Sacramento, California
Clinical Trial Site
San Francisco, California
Clinical Trial Site
Aurora, Colorado
Clinical Trial Site
New Haven, Connecticut
Clinical Trial Site
Gainesville, Florida
Clinical Trial Site
Jacksonville, Florida
Clinical Trial Site
Maitland, Florida
Clinical Trial Site
Naples, Florida
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Lexington, Kentucky
Clinical Trial Site
New Orleans, Louisiana
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Plymouth, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
Hackensack, New Jersey
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Durham, North Carolina
Clinical Trial Site
Canton, Ohio
Clinical Trial Site
Cleveland, Ohio
Clinical Trial Site
Abington, Pennsylvania
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Pittsburgh, Pennsylvania
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Houston, Texas
Clinical Trial Site
San Antonio, Texas
Clinical Trial Site
Seattle, Washington
Clinical Trial Site
Adelaide, Australia
Clinical Trial Site
Brisbane, Australia
Clinical Trial Site
Heidelberg, Australia
Clinical Trial Site
Nedlands, Australia
Clinical Trial Site
Parkville, Australia
Clinical Trial Site
Calgary, Canada
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.